Clinical Trial

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Completed Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
Protocol Amendment History 2 changes
critical Trial completed 2026-06-17
minor Completion moved earlier: 2026-11-14 -> 2026-05-20 2026-06-17
Trial Details
NCT Number NCT07264517
Lead Sponsor Instituto Grifols, S.A.
Conditions Dry Eye Disease
Enrollment 103 participants
Start Date 2025-11-03
Primary Completion 2026-05-20 (estimated)
Study Completion 2026-05-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-16